Amgen Inc. (AMGN)
Why Amgen Stock Is Paying Off Big For Long-Term Investors
Amgen's (AMGN) decade-long commitment to shareholder value is underscored by a staggering $86 billion capital return program, a feat that firmly establishes the biotech giant as a premier player in the global market.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Amgen: Strong Mitigation Of LOE Impact, Regulatory Tensions On Tavneos Emerge
Amgen delivered a strong Q4 2025, exceeding revenue and EPS expectations and guiding for 2026 growth despite major loss of exclusivity headwinds. Key branded products Repatha, Uplizna, Evenity, Imdelltra, and Tezspire are expected to offset losses from Prolia, Xgeva, and Ravicti. Regulatory uncertainty around Tavneos adds risks, and pipeline attrition (rocatinlimab, bemarituzumab) is not ideal, but positive Repatha data and MariTide progress support the long-term thesis.
Amgen Inc. (AMGN) Q4 2025 Earnings Call Transcript
Amgen Inc. (AMGN) Q4 2025 Earnings Call Transcript
Here's What Key Metrics Tell Us About Amgen (AMGN) Q4 Earnings
Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amgen (AMGN) Q4 Earnings and Revenues Beat Estimates
Amgen (AMGN) came out with quarterly earnings of $5.29 per share, beating the Zacks Consensus Estimate of $4.76 per share. This compares to earnings of $5.31 per share a year ago.
Amgen Logs Higher Fourth-Quarter Revenue on Double-Digit Volume Boost
The biotechnology company reported a quarterly profit of $1.33 billion, attributing its boost in earnings to higher revenue and lower net unrealized losses on equity investments.
Amgen quarterly results beat Street estimates on higher sales, lower tax rate
Amgen on Tuesday reported fourth-quarter financial results that came in ahead of Wall Street expectations, driven by a 7% increase in drug sales and a lower tax rate.
Amgen (AMGN) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Countdown to Amgen (AMGN) Q4 Earnings: Wall Street Forecasts for Key Metrics
Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Amgen Set to Report Q4 Earnings: What Investors Should Know
AMGN stock is in focus ahead of Q4 earnings, with biosimilar pressure and newer drug growth shaping expectations for the quarter.
Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
